Daniel Roberto Magdaleno Rodriguez
National Polytechnic Institute, Mexico
Daniel Roberto Magdaleno Rodriguez is Mexican medical student of Superior School of Medicine (School of Medicine) at National Polytechnic Institute. He is a junior researcher who has been working at the obesity center of the School since 2013 on different research lines regargding obesity, diabetes, fatty liver, metabolic syndrome and hypertension. His most important recent research is focused on drug effectiveness and security for obesity and fatty livertreatment. He is also founder and CEO of AIMEDS A.C.
Obesity has become a public global health, we can not lose sight that this disease has reached epidemic global proportions, which is why the World Health Organization (WHO by the acronym in English) calls obesity as the epidemic of the century. The purpose of this study was to evaluate the efficacy and safety of anfepramona in patients with obesity against patients who recieve a placebo. It was a longitudinal, prospective and comparative study during 6 months. This study was conducted under 200 exogenous obese patients, aged between 18 and 60 years of both sexs with Body Mass Index (BMI by the acronym in English) between 30 and 45 kg/m2 Patients were randomized into two groups of 100 subjects each and were administered for six months with anfepramona (group 1) or placebo (group 2). All patients were under medical supervision during the six months of treatment and baseline blood determinations of glucose, total cholesterol, HDL and LDL, triglycerides and liver enzymes were made, these determinations were also made at the end of the study and compared with the initial figures, results were obtained Significant in different variables.